Adding first-line pembrolizumab to CRT in locally advanced HNSCC does not significantly prolong survival or event-free survival Presented ByProf. Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc, Belgium TrialPhase 3, KEYNOTE-412 ConferenceESMO 2022 17 November, 2022 01:12